Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Jul 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Range resistance ⢠Cooling momentum Support Level: $21.00-$21.20 Resistance Level: $22.60-$22.90 Over the last month, ADPT has climbed about 10% in a constructive uptrend, but repeated stalls near $22.6-$22.9 show near-term resistance and limited breakout confirmation.
Sentiment & News
Key News Insights: ⢠Buy Upgrade ⢠Earnings Watch ⢠Share Sales ADPT's July headlines were mixed: a Buy-rank upgrade lifted sentiment, but caution around potentially negative Q2 earnings, insider/holder selling, and the July 29 results date keep near-term risk elevated.
AI Summary
ADPT has moved from a speculative platform story to an execution-sensitive commercial growth name, where the rerated stock now needs Q2 to prove MRD adoption can keep driving revenue and operating leverage fast enough to offset ongoing dilution and justify the higher valuation.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |